## A systematic review on diagnostic and prognostic biomarkers for bladder cancer

Umar Muhammad<sup>1</sup>, Umar Ahmad<sup>1,3\*</sup>, Buhari Ibrahim<sup>2</sup>, Aliyu Adamu Ahmad<sup>1</sup>, Haruna Usman Liman<sup>4</sup>

<sup>1</sup>Department of Anatomy, Faculty of Basic Medical Sciences, Bauchi State University, Gadau, PMB 65, Itas/Gadau, Nigeria. <sup>2</sup>Department of Physiology, Faculty of Basic Medical Sciences, Bauchi State University, Gadau, PMB 65, Itas/Gadau, Nigeria. <sup>3</sup>Institute of Pathogen Genomics, Centre for Laboratory and Systems Networks, Africa Centres for Disease Control and Prevention (Africa CDC), African Union Commission, P.O.Box 3243, Addis Ababa, Ethiopia. <sup>4</sup>Department of Surgery, College of Clinical Sciences, Abubakar Tafawa Balewa University Teaching Hospital (ATBUTH), Bauchi, Nigeria.

\*Correspondence: Dr. Umar Ahmad (email: <u>umarahmad@basug.edu.ng</u>)

### Abstract

Background: Bladder cancer is one of the most prevalent malignancies worldwide. Despite its high incidence, public awareness of the condition remains low, and it has received less research attention compared to other common cancers. Over the past 80 years, patient outcomes and treatment strategies have remained largely unchanged, with cystoscopy being the primary method for detecting bladder cancer. This procedure, often repeated during long-term surveillance due to the recurrent nature of bladder tumors, is both uncomfortable for patients and costly for healthcare providers. The identification and validation of molecular biomarkers in blood, urine, or tissue could facilitate tumour detection and reduce reliance on cystoscopy. Aim: This study aims to identify potential molecular biomarkers for bladder cancer that could improve tumour detection and lessen the need for repeated cystoscopies. Methods: A systematic review was conducted, searching for articles related to bladder cancer biomarkers in four databases: PubMed, ScienceDirect, Google Scholar, and Cochrane. Studies that met the inclusion criteria underwent title/abstract screening and full-text review. A total of twenty studies were deemed eligible for inclusion in this review. **Results**: The review identified several gene product biomarkers, including TEAD4, TPM1, TPM2, SKA3, EO1, HYAL3, MTDH, EPDR1, hTERT, KRT7, SW, ARHGAP9, XPH4, OTX1, BUB1, and Usp28. Additionally, protein product biomarkers were identified, such as A1AT, APOE, AG, CA9, IL8, MMP9, MMP10, PAI1, SCDI1, SDC1, VEGFA, CD73, TIP2, CXCL5, PCAT6, and NCR3LG1 (B7-H6). Conclusion: The study highlights the potential of various gene and protein biomarkers for the detection of bladder cancer. Further research is necessary to validate these biomarkers' diagnostic and prognostic potential in identifying bladder cancer in suspected cases.

Keywords: diagnostic, prognostic, molecular biomarkers, bladder cancer, systematic review

## **1.0 Introduction**

Bladder cancer ranks as the tenth most prevalent cancer globally, disproportionately affecting males four times more frequently than females (Lobo *et al.*, 2022). In 2020, approximately 573,000 cases of bladder cancer were reported, according to Global Cancer Incidence, Mortality, and Prevalence (GLOBOCAN) data (Tataroğlu, 2022). Tobacco use is the primary recognized cause, responsible for up to two-thirds of all bladder malignancies and 30–40% of urothelial carcinoma cases (Tataroğlu, 2022). With the world's population projected to exceed 9.7 billion by 2050, the incidence rate of bladder cancer is expected to rise, placing a significant burden on healthcare systems worldwide (Kourie *et al.*, 2022).

Bladder cancer is predominantly induced by cigarette smoking, advanced age, and male sex. The disease can present with microscopic hematuria, detected through cystoscopy and upper urinary tract imaging, which remain the gold standard for initial diagnosis (Lenis *et al.*, 2020). Genetic factors also play a role, with mutations in tumor suppressor genes such as PTEN and MSH2, linked to Cowden and Lynch syndromes, increasing the incidence of urothelial and squamous bladder cancer (Tataroğlu, 2022).

Treatment for non-muscle-invasive bladder cancer (NMIBC) involves endoscopic surgery and therapeutic interventions tailored to the risk of malignancy (de Ruiter *et al.*, 2022). Advanced technology in cystoscopy improves tumor detection and reduces recurrence risk (IBINGIRA *et al.*, 2022). For muscle-invasive bladder cancer (MIBC), more aggressive treatments such as radical surgery, urine diversion, or trimodal therapy involving surgery, chemotherapy, and radiation are recommended (de Ruiter *et al.*, 2022). Chemotherapy options continue to evolve, providing alternatives for patients with varying disease stages (Ertl *et al.*, 2022).

Recent advancements in diagnostic techniques include ultrasonography, intravascular urography (IVU), computed tomography (CT), magnetic resonance imaging (MRI), biopsy, and cytology (Konala *et al.*, 2022). Fluorescence-controlled diagnostics offer exceptional precision and sensitivity (Compérat *et al.*, 2022). Despite these advancements, the translation of genetic findings, particularly for NMIBC, into clinical practice remains limited (Malinaric *et al.*, 2022).

The emergence of precision medicine aims to address this gap by considering patient and tumor diversity to enable targeted therapies using potential biomarkers (Shimura *et al.*, 2021). Biomarkers hold the promise of improving diagnostic accuracy, predicting treatment outcomes, and enhancing therapeutic responses (Vlachostergios & Faltas, 2019). Numerous biomarkers have been investigated for their roles in screening, surveillance, and follow-up (Yutkin *et al.*, 2010). However, despite significant efforts, no biomarkers have yet been universally approved and applied in clinical practice (Yutkin *et al.*, 2010). The accurate application of potential biomarkers hinges on their reliability and validity (Grossman *et al.*, 2019).

This systematic review aims to identify and evaluate potential diagnostic and prognostic biomarkers for bladder cancer. By consolidating findings from recent studies, this review seeks to advance the understanding of biomarkers that could significantly impact the clinical management of bladder cancer.

#### 2.0 Materials and methods

## 2.1 Study design

This review was designed based on the Population, Intervention, Comparisons, and Outcomes (PICOS) framework. The population comprised patients with the presence of bladder cancer. The interventions involved the identification and analysis of biomarkers. The comparator was either diagnostic or prognostic methods. The outcomes focused on the presence or absence of potential biomarkers that could determine the presence of bladder cancer.

### 2.2 Protocol and registration

The study was registered with PROSPERO, and the registration ID is pending. The Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines were followed to ensure a systematic and transparent review process.

## 2.3 Literature search strategy

A systematic review of the literature was conducted in accordance with Cochrane Methods for systematic reviews(Henderson *et al.*, 2010). The databases PubMed (White, 2020), ScienceDirect (Gies, 2018), Google Scholar (Halevi *et al.*, 2017), and Cochrane (Kleinstäuber *et al.*, 1996), were searched for articles published between January 2012 and November 2022.

Two reviewers, Umar Muhammad and Aliyu Adamu Ahmad, independently conducted the literature search using the following keyword strategy: (((diagnostic) OR (prognostic)) OR (biomarkers)) OR (bladder cancer). Filters were applied to restrict results to the period from 2012 to 2023. Specific search terms included:

- I. "diagnosis" [MeSH Terms] OR "diagnosis" [All Fields] OR "diagnostic" [All Fields]
   OR "diagnostical" [All Fields] OR "diagnostically" [All Fields] OR "diagnostics" [All Fields]
- II. "prognostic" [All Fields] OR "prognostical" [All Fields] OR "prognostically" [All Fields] OR "prognosticate" [All Fields] OR "prognosticated" [All Fields] OR "prognosticates" [All Fields] OR "prognosticating" [All Fields] OR "prognostication" [All Fields] OR "prognostications" [All Fields] OR "prognosticator" [All Fields] OR "prognosticators" [All Fields] OR "prognosticators" [All Fields] OR "prognostics" [All Fields] OR "prognosticators" [All Fields] OR "prognosti
- III. "biomarkers" [All Fields] OR "biomarkers" [MeSH Terms] OR "biomarkers" [All Fields] OR "biomarker" [All Fields]
- IV. "urinary bladder neoplasms" [MeSH Terms] OR ("urinary" [All Fields] AND "bladder"
   [All Fields] AND "neoplasms" [All Fields]) OR "urinary bladder neoplasms" [All
   Fields] OR ("bladder" [All Fields] AND "cancer" [All Fields]) OR "bladder cancer"
   [All Fields]

The search results were exported and managed using the online systematic review software Covidence (Babineau, 2014). Duplicate articles were removed, and the remaining articles underwent further screening based on titles and abstracts. Full-text articles were then reviewed to identify studies that met the inclusion criteria.

### 2.4 Study selection

The study selection process was managed using the online systematic review software Covidence (<u>https://www.covidence.org</u>)(Babineau, 2014). This tool facilitated the organization and screening of articles retrieved from the bibliographic databases. The articles were independently screened by two reviewers based on their titles, abstracts, and the availability of full-texts.

# 2.4.1 Inclusion criteria

- I. Original research articles focused on bladder cancer.
- II. Published in English.
- III. Various study designs and participant demographics.
- IV. Studies investigating genes or proteins in blood, urine, or tissue samples.
- Comparison of the diagnostic or prognostic value of these biomarkers, including cystoscopy as a comparator.
- VI. Desired outcomes included the presence or absence of potential biomarkers and their accuracy.

# 2.4.1 Exclusion criteria

- I. Non-original research articles.
- II. Studies unrelated to bladder cancer biomarkers.
- III. Studies lacking clarity on identified biomarkers.
- IV. Studies without a comparison group.
- V. Animal or in vitro studies.
- VI. Articles not published in English.

The specified publication date range was between January 2012 and November 2022. This rigorous screening process ensured the selection of high-quality studies relevant to the systematic review's objectives, ultimately including those that met all predefined criteria.

## 2.5 Data extraction

This systematic review strictly followed the PRISMA guidelines during the data extraction phase to ensure a transparent and systematic process. Two independent reviewers meticulously gathered information on key aspects of the studies, including study design, participant characteristics, investigated biomarkers, outcomes, and statistical methods. Any discrepancies in the extracted data were resolved through consensus or, if necessary, by consulting a third reviewer, thereby maintaining the integrity and accuracy of the process. The initial data extraction was carried out by the first reviewer, who carefully collected data from the included studies. This information was then cross-checked and confirmed by the second reviewer to ensure accuracy and completeness. The extracted data was compiled into a comprehensive table, structured according to PRISMA standards.

### 3.6 Quality assessment

The quality of the included studies was independently evaluated by two reviewers using the Quality Assessment of Diagnostic Accuracy Studies (QUADAS-2) tool (Wade *et al.*, 2013). This tool is specifically designed for assessing the risk of bias in observational studies, such as cohort and case-control studies (Wade *et al.*, 2013). The QUADAS-2 tool evaluates four key domains:

- 1. **Patient Selection**: Examines the methods used to select patients and assesses whether these methods could introduce bias.
- 2. **Index Test**: Assesses the risk of bias in the conduct and interpretation of the test being evaluated.
- 3. **Reference Standard**: Evaluates the risk of bias associated with the application and interpretation of the reference standard.

4. **Flow and Timing**: Considers the potential for bias related to the timing of the index test and reference standard, as well as the flow of patients through the study.

Each domain is rated for risk of bias as "low," "high," or "some concerns." A domain is judged to have a low risk of bias if all questions for that domain are answered affirmatively. If any questions are answered negatively, the risk of bias for that domain is considered high. The "some concerns" category is used when there is insufficient data to make a clear judgment.

The independent assessments by the two reviewers were compared, and any discrepancies were resolved through discussion or consultation with a third reviewer. This rigorous process ensured a thorough and unbiased evaluation of the included studies, enhancing the reliability and validity of the review's conclusions.

#### 3.0 Results

### 3.1 Literature search

A comprehensive literature search was conducted following the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines. The objective was to identify relevant articles on bladder cancer biomarkers published from January 2012 to November 2022. The search encompassed four major databases: PubMed, ScienceDirect, Google Scholar, and Cochrane.


The search strategy employed medical subject headings (MeSH) and keywords related to bladder cancer, biomarkers, and diagnostic or prognostic outcomes. Terms included, but were not limited to, "bladder cancer," "biomarkers," "diagnostic," "prognostic," and their variations. Boolean operators "AND" and "OR" were used to refine the search results. Additionally, the reference lists of pertinent articles were hand-searched to uncover any studies that the initial electronic search might have missed.

Two independent reviewers, Umar Muhammad and Aliyu A. Ahmad, conducted the literature search to ensure comprehensive coverage and minimize bias. The search yielded a total of 2950 articles. Following this, approximately 650 duplicates were removed, leaving 2300 articles for further screening.

The remaining articles underwent a rigorous screening process based on their titles and abstracts, which resulted in the exclusion of a significant number of studies. The full texts of the remaining articles were then thoroughly reviewed. This process led to the exclusion of additional articles that did not meet the inclusion criteria. Ultimately, 35 articles were assessed for conformity with our inclusion criteria, of which 15 were excluded for various reasons.

Following this comprehensive screening process, 20 articles were deemed eligible and included in the final quantitative synthesis. These studies formed the basis for the systematic review and comprehensive analysis of bladder cancer biomarkers. The entire literature search process is summarized in Figure 1, which adheres to PRISMA standards, detailing the databases searched and the number of articles screened and selected for the systematic review.

	_	Identification of stud	lies via da	tabases and registers
Id en tif ic at io n		Records identified from: PubMed (n = 905) ScienceDirect (n = 905) Google Scholar (n= 800) Cochrane (n= 129)		Records removed <i>before</i> <i>screening</i> : Duplicate records removed (n = 97) Records marked as ineligible by automation tools (n = 223)



**Figure 1: PRISMA flow diagram**. PRISMA flow diagram illustrating the systematic review process, detailing the database searches and the number of articles screened, assessed for eligibility, and included in the qualitative synthesis. Out of 2950 articles identified through database searches, 20 articles met the inclusion criteria and were selected for qualitative analysis.

## 3.2 Characteristics of the data extracted from the studies

The data extracted from the twenty selected studies focused on identifying diagnostic and

prognostic biomarkers for bladder cancer, spanning from January 2012 to November 2022

(Table 1). These studies included original research articles with varied designs, such as cohort and case-control studies, conducted across multiple countries, including China, Korea, Iran, Finland, and the USA. This geographical diversity underscores the global interest in enhancing bladder cancer diagnosis and management through biomarker identification.

The studies collectively identified thirteen gene product biomarkers and seven protein product biomarkers. Gene biomarkers discovered included TEAD4, TPM1, TPM2, SKA3, ENO1, HYAL3, MTDH, EPDR1, hTERT, KRT7, SW, ARHGAP9, NXPH4, OTX1, BUB1, and Usp28. Protein biomarkers identified were A1AT, APOE, AG, CA9, IL8, MMP9, MMP10, PAI1, SDC11, SDC1, VEGFA, CD73, TIP2, CXCL5, PCAT6, and NCR3LG1 (B7-H6).

These biomarkers were detected in various sample types, including tissue, urine, and blood, reflecting the diverse methodologies employed. The biomarkers are associated with multiple pathways such as the PI3K/AKT pathway, immune-related pathways, cell cycle pathways, and glycolysis pathways. These pathways play crucial roles in tumor development, immune cell infiltration, and cancer cell motility, which are critical for understanding the mechanisms underlying bladder cancer progression. The biomarkers were linked to different stages of bladder cancer, ranging from non-muscle invasive bladder cancer (NMIBC) to muscle-invasive bladder cancer (MIBC). For instance, TEAD4 was identified as a prognostic biomarker promoting epithelial to mesenchymal transition (EMT) in bladder cancer cells by activating the PI3K/AKT pathway, enhancing cell migration and invasion. TPM1 and TPM2 were highlighted as useful diagnostic indicators linked to immune cell invasion in bladder cancer, while SKA3 was noted for its association with immune infiltration affecting patient prognosis.

The studies also reported the potential of certain protein biomarkers for clinical application. A1AT, APOE, AG, CA9, IL8, MMP9, MMP10, PAI1, SDCI1, SDC1, and VEGFA were part of a multiplex Oncuria test that accurately identifies and monitors bladder cancer through urine samples. Similarly, CD73, an adenosine-producing cell surface enzyme found in blood, was proposed as a prognostic biomarker for bladder cancer.

Despite the promising findings, the implementation of these biomarkers in clinical practice is still under research. The studies collectively highlight the need for further investigation to validate the diagnostic and prognostic potential of these biomarkers and determine their clinical applicability.

Study ID	Author & Year	Country	Symbol of Biomarker	Product	Source	Pathways	Stage of cancer	Functions of the Biomarkers
1	Chi <i>et al.</i> (2022)	China	TEAD4	Gene	Tissue	P13K/AKT	T3-T4	<i>TEAD4</i> promotes epithelial to mesenchymal transition (EMT) of bladder cancer (BC) cells by activating the PI3K/AKT pathway, which enhances cell migration and invasion. <i>TEAD4</i> is a good prognosis biomarker. These results offer a good target for the treatment of metastatic BC in addition to an efficient biomarker for prognosis prediction.
2	Yan <i>et al</i> .(2022)	China	<i>TPM1</i> and <i>TPM2</i>	Gene	Tissue	immune inhibition	T2-T3 and T4-T1	<i>TPM1</i> and <i>TPM2</i> are useful diagnostic biomarkers for bladder cancer. <i>TPM1</i> serve as a predictor of bladder cancer outcome. The invasion of different immune cells in bladder cancer is also linked to Tropomyosin (TM). TM may have influenced the development of bladder cancer through immune inhibition.
3	Wang <i>et al.</i> (2022)	China	SKA3	Gene	Tissue	M2 macrophages and Th2 cells		<i>SKA3</i> is linked to immune infiltration and can affect a patient's prognosis for bladder cancer. In particular, <i>SKA3</i> may affect the development of M2 macrophage and Th2 cells, which may

**Table 1: Summarized the data extracted and analysed from all the twenty selected studies.** All studies were published from January 2012 onwards. Eleven articles focused on prognostic biomarkers, while nine articles focused on diagnostic biomarkers.

								aid in the growth and spread of bladder cancer. <i>SKA3</i> may therefore be a useful prognostic biomarker for bladder cancer.
4	Huang <i>et al.</i> (2022)	China	ENOs	Gene	Tissue	Glycolysis pathway	T1-T2-T4	<i>ENO1</i> was substantially correlated with tumor aggressiveness and abnormality which is over expressed in bladder (BC). Up regulation of <i>ENO1</i> also predicted worse clinical outcomes. These findings suggested that <i>ENO1</i> could be a useful diagnostic biomarker for BC. Additionally, there was a striking correlation between <i>ENO1</i> expression and immune cell infiltration in the tumor microenvironment (TME) of BC. Together, our findings contribute to a deeper comprehension of <i>ENO1</i> 's actions as well as its potential translational applications for BC diagnosis and treatment.
5	Liu <i>et al</i> . (2022)	China	HYAL3	Gene	Tissue	β-1,4-glycosidic bond between 2-acetyl-D-deoxygenation- D-glucose and D-glucuronic acid	T1-T4	A shorter overall survival (OS) among bladder cancer BC patients may be predicted by a greater <i>HYAL3</i> expression level. Additionally, in BC, <i>HYAL3</i> was linked to a variety of invading immune cells, including Th cells, T cells, CD8+ T cells, cytotoxic cells, B cells, etc. These findings suggest that <i>HYAL3</i> may be used as a biomarker for the diagnosis and

								management of BC.
6	Zhou <i>et al.</i> (2012)	China	MTDH	Gene	Tissue			These findings determined that, the possibility of using <i>MTDH</i> as a prognostic biomarker for bladder cancer patients as well as a useful clinical marker of cancer development, may serve as a potential predictor for the diagnosis of bladder cancer.
7	Yang <i>et al</i>	China	EPDR1	Gene	Tissue	PI3K/AKT pathway,	T2, T3,	EPDR1 could be identified in BC
	.(2021)	021)				Cytokine receptor interaction and apoptosis.	T4	patients as a novel biomarker with prognostic significance and could be used as a biomarker or target for the diagnosis or management of BC.
8	Hirasawa <i>et</i> <i>al.</i> (2021)	USA	A1AT, APOE, AG, CA9, IL8, MMP9, MMP10, PAI1, SDCI1, SDC1, and VEGFA	Protein	Urine		Ta, Tis, T1 and T2	In a NIMBC clinical patient, the multiplex Oncuria test can effectively and accurately identify and monitor bladder cancer. A biomarker panel's urinary levels allowed for the precise classification of bladder cancer patients and healthy controls.
9	Yahyazadeh et al.(2021)	Iran	hTERT,KRT7 and SW	Gene	Urine	Extrinsic and intrinsic pathway of apoptosis	Ta, T1, T2 and T3.	The diagnostic potential of monitoring bladder cancer by evaluating the amounts of <i>hTERT</i> , <i>SW</i> , and <i>KRT7</i> mRNA in the urine will help in determined the presence of bladder cancer. The identification of these

markers in samples of voided urine shows higher sensitivity than cytology. For the diagnostic and follow-up of low-grade transitional cell carcinoma (TCC) of the bladder, the collection of these markers provides a potential test and instrument for a diagnostic, and extremely specific management for BC

10	Koivisto <i>et al.</i> (2019)	Finland	CD73	Protein	Blood	By catalyzing the hydrolysis of adenosine monophosphate in to adenosine and phosphate	T2	In many different cell types, CD73 is an adenosine-producing cell surface enzyme, and is a potential prognostic biomarker for bladder cancer.
11	Piao <i>et al.</i> (2019)	Korea	ARHGAP9	Gene	Tissue	MAPK signaling pathway	T4	These findings identify <i>ARHGAP9</i> as potential oncogenes in BC that may be used as a unique prognostic marker to classify NMIBC and MIBC patients into categories with both positive and negative prognoses.
12	Sun <i>et al.</i> (2022)	China	NXPH4	Gene	Tissue	Immune related pathway	T1	NXPH4 was discovered by the current investigation to be a unique prognostic molecular marker linked to immune cell infiltration in BC. These results might open new perspectives on how BC prognosis is determined as well as guide future research on BC tumor immunity.

13	Jiang <i>et al</i> . (2022)	China	TIPE2	Protein	Tissue	Tollike receptor (TLR) and T cell receptor (TCR) signaling pathways.	T1-T2	TIPE2 was over express in clinicopathological diagnosis, and prognoses in bladder urothelial cancer. Overall, the result suggests that TIPE2 could be employed as a potential biomarker for bladder urothelial cell carcinoma patient's prognosis and disease management.
14	Jiang <i>et al.</i> (2021)	China	OTX1	Gene	Tissue	Cell cycle-related pathways		<i>OTX1</i> is a potential gene biomarker for the diagnosis and prognosis of BC. The gene indicated carcinogenic effects by increasing the development and motility of cancer cells through the regulation of cell cycle-related pathways and could serve as a potential biomarker for bladder cancer management.
15	Piao <i>et al.</i> (2021)	Korea	BUB1	Gene		Cell cycle pathways	Ta, T1	It was proposed that <i>BUB1</i> controls the G2/M transition to increase bladder cancer cell proliferation, which increases the possibility that it could act as a prognostic biomarker for NMIBC.
16	Zhu <i>et al.</i> (2015)	China	CXCL5	Protein	Urine and Tissue	P13-AKT, and ERK1/2 signaling pathways	Т	It was determines that CXCL5 protein is a potential prognostic biomarker for bladder cancer tissue and a novel marker for diagnosis of BC in urine.

17	Zhang <i>et al.</i> (2020)	China	PCAT6	Protein	Tissue		T1-T4	In this article PCAT6 protein was shown to be significantly expressed in BC tissues, cells, and patient serum. However, individuals with BC experienced lower survival rates when PCAT6 expression was present. The research results of our investigation suggested that the lncRNA PCAT6 may contribute as a potential marker for the diagnosis and prognosis of bladder cancer in clinical examination.
18	Zhao <i>et al.</i> (2021)	China	NCR3LG1 (B7-H6)	Protein	Tissue	Induced NKp30-mediated cell activation		According to this study, NCR3LG1 protein has a role in the growth of human BC and has the potential to be used as a prognostic biomarker for the BC. Increased NCR3LG1 expression i a useful prognostic BC biomarker that could help I the management of bladder cancer.
19	Esawy <i>et al.</i> (2019)	Egypt	Irisin	Protein	Tissue	Irisin is modulated by peroxisome proliferator-activated receptor-g coactivator 1. The precursor protein is exposed to proteolytic cleavage then the irisin is released to the circulation.	T1-T4	Iirisin protein seems to be an excellent diagnostic and prognostic biomarker for bladder cancer management.

20	Guo et	China	Usp28	Gene	Tissue	GSK3-FBW7	Ta, T1,	It was determining that Usp28
	al. (2013)						T2, T3,	expression was found to be a potential
							Τ4.	prognostic biomarker for BC
								management.

#### **4.3 Quality Assessment**

The quality of the included studies was evaluated using the Quality Assessment of Diagnostic Accuracy Studies (QUADAS-2) tool. This tool assesses the risk of bias across four domains: patient selection, index test, reference standard, and flow and timing. A study was declared to have a low risk of bias in a domain if most of the review questions for that domain were answerable and scored positively. All twenty studies included in this systematic review were assessed for quality, and the majority were found to be of high quality. Specifically, eighteen of the included studies (90%) were rated as having a low risk of bias across all assessed domains. These studies provided clear and comprehensive information on patient selection, the index test, reference standards, and the flow and timing of the diagnostic process, thereby ensuring robust and reliable results.

Two studies (10%) were rated as having some concerns regarding bias, primarily due to incomplete reporting in the flow and timing domain. These concerns, however, were not significant enough to exclude the studies from the review. Instead, they indicate areas where future research can improve reporting standards to ensure complete transparency and reproducibility.

Overall, all twenty studies were deemed to have moderate to high quality, with the majority exhibiting low risk of bias. Consequently, they were included in the quantitative synthesis,

providing a reliable basis for the systematic review's findings on diagnostic and prognostic

biomarkers for bladder cancer.

			Risl	of bias dom	ains		
		D1	D2	D3	D4	Overall	
	Chi et al. (2022)	+	+	+	+	+	
	Yan et al .(2022)	+	+	+	+	+	
	Wang et al. (2022)	+	+	-	+	+	
	Huang et al. (2022)	+	-	+	+	+	
	Liu et al. (2022)	+	+	+	+	+	
	Zhou et al. (2012)	+	+	-	+	+	
	Yang et al .(2021)	+	-	+	+	+	
	Hirasawa et al. (2021)	+	-	+	+	+	
	Yahyazadeh et al.(2021)	+	+	×	+	+	
dy	Koivisto et al. (2019)	+	+	-	+	+	
Study	Piao et al. (2019)	+	+	+	-	+	
	Sun et al. (2022)	+	+	+	-	+	
	Jiang et al. (2022)	+	+	+	+	+	
	Jiang et al. (2021)	+	×	+	+	+	
	Piao et al. (2021)	+	+	+	+	+	
	Zhu et al. (2015)	+	+	+	+	+	
	Zhang et al. (2020)	+	+	+	+	+	
	Zhao et al. (2021)	+	-	+	+	+	
	Esawy et al. (2019)	+	×	+	+	+	
	Guo et al. (2013)	+	+	-	+	+	
		Domains: D1: Patient sel D2: Index test. D3: Reference D4: Flow & tim	standard.	Juc - -	Judgement High - Some concerns Low		

**Figure 2:** Evaluation of Bias Risk in Included Prospective Studies Using the Newcastle-Ottawa Scale.

## Discussion

This systematic review identified twenty potential biomarkers for the diagnosis and prognosis of bladder cancer, consisting of thirteen gene products (TEAD4, TPM1, TPM2, SKA3, ENO1, HYAL3, MTDH, EPDR1, hTERT, KRT7, SW, ARHGAP9, NXPH4, OTX1, BUB1, and Usp28) and seven protein products (A1AT, APOE, AG, CA9, IL8, MMP9, MMP10, PAI1, SDC11, SDC1, VEGFA, CD73, TIP2, CXCL5, PCAT6, NCR3LG1 (B7-H6), and irisin). These biomarkers were identified through various methodologies using tissue, urine, and blood samples, and are involved in diverse pathways, including the PI3K/AKT pathway, immune-related pathways, and cell cycle pathways.

The study by Chi *et al.*, (2022) highlighted TEAD4 as a potential prognostic biomarker that promotes epithelial to mesenchymal transition (EMT) in bladder cancer cells, enhancing cell migration and invasion through the PI3K/AKT pathway. This finding aligns with previous research suggesting the role of the PI3K/AKT pathway in cancer progression. Similarly, Yan *et al.*, (2022) identified TPM1 and TPM2 as useful diagnostic indicators linked to immune cell invasion in bladder cancer, supporting the notion that immune system interactions play a critical role in tumor development.

SKA3, identified by Wang et al., (2022), was linked to immune infiltration and was reported to affect a patient's prognosis for bladder cancer. This is consistent with other studies that have shown the involvement of immune cells, such as M2 macrophages and Th2 cells, in cancer progression. Huang *et al.*, (2022) found that ENO1 was substantially correlated with tumor

aggressiveness and abnormality, being overexpressed in bladder cancer. This upregulation of ENO1 predicted worse clinical outcomes, suggesting its potential as a diagnostic biomarker, which corroborates findings from other cancers where ENO1 has been implicated.

Liu *et al.*, (2022) determined that a shorter overall survival among bladder cancer patients may be predicted by a greater HYAL3 expression level. This biomarker was linked to a variety of invading immune cells, further emphasizing the role of the immune environment in cancer prognosis. Zhou *et al.*, (2012) suggested the possibility of using MTDH as a prognostic biomarker for bladder cancer patients, a finding that resonates with other studies on cancer progression markers. Hirasawa et al., (2021) demonstrated the diagnostic potential of a panel of urine-based proteins, including A1AT, APOE, AG, CA9, IL8, MMP9, MMP10, PAI1, SDCI1, SDC1, and VEGFA, which could be useful in bladder cancer management. This aligns with the trend towards non-invasive diagnostic techniques.

Yahyazadeh *et al.*, (2021) reported the diagnostic potential of monitoring bladder cancer by evaluating the amounts of hTERT, SW, and KRT7 mRNA in urine. This method shows higher sensitivity than cytology, providing a non-invasive approach for diagnosing and following up on low-grade transitional cell carcinoma (TCC) of the bladder. Koivisto *et al.*, (2019) identified CD73, an adenosine-producing cell surface enzyme, as a potential prognostic biomarker, supporting findings from other studies on adenosine's role in cancer progression. Piao *et al.*, (2020) identified ARHGAP9 as potential oncogenes in bladder cancer that may be used as unique prognostic markers, adding to the body of evidence on genetic markers in cancer classification.

Sun *et al.*, (2022) discovered NXPH4 as a unique prognostic molecular marker linked to immune cell infiltration in bladder cancer. This finding could guide future research on bladder cancer tumor immunity. Jiang *et al.*, (2022) determined that TIPE2 was overexpressed in clinicopathological diagnosis and prognosis in bladder urothelial cancer, suggesting its employment as a potential protein biomarker for disease management. Jiang *et al.*, (2021) also identified OTX1 as a potential gene for the diagnosis and prognosis of bladder cancer, with carcinogenic effects through cell cycle-related pathways. Piao *et al.*, (2021) proposed that BUB1 controls the G2/M transition to increase bladder cancer cell proliferation, potentially acting as a prognostic biomarker for NMIBC. Zhang *et al.*, (2020) identified CXCL5 protein as a potential prognostic biomarker for bladder cancer tissue and a novel marker for diagnosis in urine.

Zhang *et al.*, (2020) demonstrated that PCAT6 protein was significantly expressed in bladder cancer tissues, cells, and patient serum, with lower survival rates associated with its expression. This investigation suggested that lncRNA PCAT6 may serve as a potential marker for diagnosis and prognosis in clinical examinations. According to Esawy & Abdel-Samd, (2020), NCR3LG1 protein has a role in the growth of human bladder cancer and could be used as a prognostic biomarker, with increased expression being a useful indicator.

Lastly, Guo *et al.*, (2014) determined that Usp28 expression was found to be a potential prognostic biomarker for bladder cancer. Despite the identification of several potential biomarkers in blood, tissue, and urine, their implementation in clinical application remains

limited. Further studies are required to validate these biomarkers and establish their clinical utility.

## Conclusion

This systematic review identified twenty potential biomarkers that could aid in the detection and management of bladder cancer. Among these, thirteen were gene product biomarkers (TEAD4, TPM1, TPM2, SKA3, ENO1, HYAL3, MTDH, EPDR1, hTERT, KRT7, SW, ARHGAP9, NXPH4, OTX1, BUB1, and Usp28) and seven were protein product biomarkers (A1AT, APOE, AG, CA9, IL8, MMP9, MMP10, PAI1, SDC11, SDC1, VEGFA, CD73, TIP2, CXCL5, PCAT6, NCR3LG1 (B7-H6), and irisin). These biomarkers were identified in patients with bladder cancer and are involved in various pathways, highlighting their potential role in disease progression and prognosis.

The findings underscore the significant promise of these biomarkers in improving bladder cancer diagnosis and reducing the need for invasive procedures like cystoscopy. However, the studies reviewed provided limited details on the clinical application and validation of these biomarkers. Therefore, further research is essential to confirm their diagnostic and prognostic value, establish standardized protocols for their use, and integrate them into clinical practice.

In conclusion, while this review highlights the potential of gene and protein biomarkers in bladder cancer management, extensive validation and clinical trials are necessary to translate these findings into practical diagnostic tools and therapeutic targets. Future studies should focus on large-scale validation, the development of non-invasive testing methods, and the

exploration of these biomarkers' roles in personalized medicine to enhance patient outcomes in bladder cancer.

# List of abbreviations

Adenosine triphosphate (ATP)

Bladder cancer (BC)

Bladder tumour antigen (BTA)

Cyclin D1 (CCD1),

Epithelial to mesenchymal transition (EMT)

Intrasonography intravascular urography (IVU)

Muscles invasive bladder cancer (MIBC)

Non-muscle invasive bladder cancer (NMIBC)

Nuclear matrix protein 22 (MP22).

# Declaration

Competing interests: Authors declare that there is no conflict of interest.

**Funding**: This research received no specific grant from any funding agency in the public, commercial or not-for-profit sectors.

**Authors' contributions:** Conceived and designed the study: UA. Performed literature mining and wrote the first draft: UM and UA. Reviewed and revised the draft: BI. Conducted the analysis: UM. Reviewed the final draft: AAA and HUL.

## Reference

Babineau, J. (2014). Product review: Covidence (systematic review software). *Journal of the Canadian Health Libraries Association/Journal de l'Association Des Bibliothèques de La Santé Du Canada*, *35*(2), 68–71.

Batista, T. M., Jayavelu, A. K., Wewer Albrechtsen, N. J., Iovino, S., Lebastchi, J., Pan, H., Dreyfuss, J. M., Krook, A., Zierath, J. R., Mann, M., & Kahn, C. R. (2020). A Cell-Autonomous Signature of Dysregulated Protein Phosphorylation Underlies Muscle Insulin Resistance in Type 2 Diabetes. *Cell Metabolism*, *32*(5), 844-859.e5. https://doi.org/10.1016/j.cmet.2020.08.007

Chi, M., Liu, J., Mei, C., Shi, Y., Liu, N., Jiang, X., Liu, C., Xue, N., Hong, H., Xie, J., Sun, X., Yin, B., Meng, X., & Wang, B. (2022). TEAD4 functions as a prognostic biomarker and triggers EMT via PI3K/AKT pathway in bladder cancer. *Journal of Experimental & Clinical Cancer Research*, *41*(1), 175. https://doi.org/10.1186/s13046-022-02377-3

Compérat, E., Amin, M. B., Cathomas, R., Choudhury, A., De Santis, M., Kamat, A., Stenzl, A., Thoeny, H. C., & Witjes, J. A. (2022). Current best practice for bladder cancer: a narrative review of diagnostics and treatments. *The Lancet*.

de Ruiter, B.-M., van Hattum, J. W., Lipman, D., de Reijke, T. M., van Moorselaar, R. J. A., van Gennep, E. J., Piet, A. H. M., Donker, M., van der Hulle, T., & Voortman, J. (2022). Phase 1 Study of Chemoradiotherapy Combined with Nivolumab±Ipilimumab for the Curative Treatment of Muscle-invasive Bladder Cancer. *European Urology*, *82*(5), 518–526.

Ertl, I. E., Lemberger, U., Ilijazi, D., Hassler, M. R., Bruchbacher, A., Brettner, R., Kronabitter, H., Gutmann, M., Vician, P., & Zeitler, G. (2022). Molecular and Pharmacological Bladder Cancer Therapy Screening: Discovery of Clofarabine as a Highly Active Compound. *European Urology*.

Esawy, M. M., & Abdel-Samd, K. M. (2020). The diagnostic and prognostic roles of serum irisin in bladder cancer. *Current Problems in Cancer*, *44*(4). https://doi.org/10.1016/j.currproblcancer.2019.100529

Gies, T. (2018). The ScienceDirect accessibility journey: A case study. *Learned Publishing*, *31*(1).

Grossman, H. B., Bellmunt, J., & Black, P. C. (2019). Can biomarkers guide the use of neoadjuvant chemotherapy in T2 bladder cancer? *European Urology Oncology*, 2(5), 597–602.

Guo, G., Xu, Y., Gong, M., Cao, Y., & An, R. (2014). USP28 is a potential prognostic marker for bladder cancer. *Tumor Biology*, *35*(5), 4017–4022. https://doi.org/10.1007/s13277-013-1525-1

Halevi, G., Moed, H., & Bar-Ilan, J. (2017). Suitability of Google Scholar as a source of scientific information and as a source of data for scientific evaluation—Review of the literature. *Journal of Informetrics*, *11*(3), 823–834.

Hatakeyama, S., Narita, S., Okita, K., Narita, T., Iwamura, H., Fujita, N., Inokuchi, J., Matsui, Y., Kitamura, H., & Ohyama, C. (2022). Management of bladder cancer in older patients. *Japanese Journal of Clinical Oncology*, *52*(3), 203–213.

Henderson, L. K., Craig, J. C., Willis, N. S., Tovey, D., & Webster, A. C. (2010). How to write a Cochrane systematic review. *Nephrology*, *15*(6), 617–624.

Hirasawa, Y., Pagano, I., Chen, R., Sun, Y., Dai, Y., Gupta, A., Tikhonenkov, S., Goodison, S., Rosser, C. J., & Furuya, H. (2021). Diagnostic performance of Oncuria<sup>TM</sup>, a urinalysis test for bladder cancer. *Journal of Translational Medicine*, *19*(1), 1–10. https://doi.org/10.1186/s12967-021-02796-4

Huang, Z., Yan, Y., Wang, T., Wang, Z., Cai, J., Cao, X., Yang, C., Zhang, F., Wu, G., & Shen, B. (2022). Identification of ENO1 as a prognostic biomarker and molecular target among ENOs in bladder cancer. *Journal of Translational Medicine*, *20*(1), 1–15. https://doi.org/10.1186/s12967-022-03509-1

IBINGIRA, T. J., ABRAHAMS, O., & DAN, N. (2022). Health related quality of life and associated factors among patients with urinary bladder cancer at Mulago National Referral hospital-a cross sectional study.

Jiang, L., Zuo, Z., Lin, J., & Yang, C. (2021). Orthodenticle homeobox OTX1 is a potential prognostic biomarker for bladder cancer. *Bioengineered*, *12*(1), 6559–6571. https://doi.org/10.1080/21655979.2021.1974646

Jiang, Y., Zhang, Z., Wang, X., Feng, Z., Hong, B., Yu, D., & Wang, Y. (2022). A Novel Prognostic Factor TIPE2 in Bladder Cancer. *Pathology and Oncology Research*, 28(March), 1–8. https://doi.org/10.3389/pore.2022.1610282

Kleinstäuber, M., Witthöft, M., Steffanowski, A., Van Marwijk, H., Hiller, W., & Lambert, M. J. (1996). *Cochrane database of systematic reviews*.

Koivisto, M. K., Tervahartiala, M., Kenessey, I., Jalkanen, S., Boström, P. J., & Salmi, M. (2019). Cell-type-specific CD73 expression is an independent prognostic factor in bladder cancer. *Carcinogenesis*, *40*(1), 84–92. https://doi.org/10.1093/carcin/bgy154

Konala, V. M., Adapa, S., & Aronow, W. S. (2022). Immunotherapy in bladder cancer. *American Journal of Therapeutics*, 29(3), e334–e337.

Kourie, H. R., Succar, B., Chouery, E., Mehawej, C., Ahmadieh, N., Zouein, J., Mardirossian, A., Jalkh, N., Sleilaty, G., Kattan, J., & Nemr, E. (2022). Genetic susceptibility of bladder cancer in the Lebanese population. *BMC Medical Genomics*, *15*(1), 217. https://doi.org/10.1186/s12920-022-01372-z

Lenis, A. T., Lec, P. M., Chamie, K., & MSHS, M. D. (2020). Bladder Cancer: A Review. *JAMA*, *324*(19), 1980–1991. https://doi.org/10.1001/jama.2020.17598

Liu, J. peng, Fang, Y. tong, Jiang, Y. fan, & Lin, H. (2022). HYAL3 as a potential novel marker of BLCA patient prognosis. *BMC Genomic Data*, 23(1), 1–17. https://doi.org/10.1186/s12863-022-01070-w

Lobo, N., Afferi, L., Moschini, M., Mostafid, H., Porten, S., Psutka, S. P., Gupta, S., Smith, A. B., Williams, S. B., & Lotan, Y. (2022). Epidemiology, Screening, and Prevention of Bladder Cancer. *European Urology Oncology*. https://doi.org/https://doi.org/10.1016/j.euo.2022.10.003

Malinaric, R., Mantica, G., Lo Monaco, L., Mariano, F., Leonardi, R., Simonato, A., Van der Merwe, A., & Terrone, C. (2022). The Role of Novel Bladder Cancer Diagnostic and Surveillance Biomarkers—What Should a Urologist Really Know? *International Journal of Environmental Research and Public Health*, *19*(15), 9648.

Piao, X. M., Jeong, P., Yan, C., Kim, Y. H., Byun, Y. J., Xu, Y., Kang, H. W., Seo, S. P.,
Kim, W. T., Lee, J. Y., Kim, I. Y., Moon, S. K., Choi, Y. H., Cha, E. J., Yun, S. J., & Kim,
W. J. (2020). A novel tumor suppressing gene, ARHGAP9, is an independent prognostic biomarker for bladder cancer. *Oncology Letters*, *19*(1), 476–486.
https://doi.org/10.3892/ol.2019.11123

Piao, X. M., You, C., Byun, Y. J., Kang, H. W., Noh, J., Lee, J., Lee, H. Y., Kim, K., Kim, W. T., Yun, S. J., Lee, S. C., Kang, K., & Kim, Y. J. (2021). Prognostic value of bub1 for predicting non  $\Box$  muscle  $\Box$  invasive bladder cancer progression. *International Journal of Molecular Sciences*, 22(23). https://doi.org/10.3390/ijms222312756

Raghavan, D., & Huben, R. (1995). Management of bladder cancer. *Current Problems in Cancer*, *19*(1), 5–63. https://doi.org/https://doi.org/10.1016/S0147-0272(07)80002-X

Shimura, S., Matsumoto, K., Shimizu, Y., Mochizuki, K., Shiono, Y., Hirano, S., Koguchi, D., Ikeda, M., Sato, Y., & Iwamura, M. (2021). Serum Epiplakin Might Be a Potential

Serodiagnostic Biomarker for Bladder Cancer. In *Cancers* (Vol. 13, Issue 20). https://doi.org/10.3390/cancers13205150

Smith, A. B. (2018). Recent developments in the management of bladder cancer: Introduction. *Urologic Oncology: Seminars and Original Investigations*, *36*(3), 95–96. https://doi.org/https://doi.org/10.1016/j.urolonc.2017.10.026

Sun, X., Xin, S., Jin, L., Zhang, Y., & Ye, L. (2022). Neurexophilin 4 is a prognostic biomarker correlated with immune infiltration in bladder cancer. *Bioengineered*, *13*(5), 13986–13999. https://doi.org/10.1080/21655979.2022.2085284

Tataroğlu, Ö. D. (2022). Bladder cancer: A mini review. *Unico's Review*, *1*(1 SE-REVIEW), 1–4. https://doi.org/10.5281/zenodo.7265789

Vlachostergios, P. J., & Faltas, B. M. (2019). The molecular limitations of biomarker research in bladder cancer. *World Journal of Urology*, *37*(5), 837–848.

Zhao, L., Lian, T., Li, J., Wei, S., Li, H., Li, C., & Wang, H. (2021). NCR3LG1 (B7-H6) is a potential prognostic factor for bladder cancer patients. *Biomarkers*, *26*(3), 260–267. https://doi.org/10.1080/1354750X.2021.1883110

Zhou, J., Li, J., Wang, Z., Yin, C., & Zhang, W. (2012). Metadherin is a novel prognostic marker for bladder cancer progression and overall patient survival. *Asia-Pacific Journal of Clinical Oncology*, 8(3). https://doi.org/10.1111/j.1743-7563.2012.01541.x

Zhu, C.-Z., Ting, H.-N., Ng, K.-H., & Ong, T.-A. (2019). A review on the accuracy of bladder cancer detection methods. *Journal of Cancer*, *10*(17), 4038.

Zhu, X., Qiao, Y., Liu, W., Wang, W., Shen, H., Lu, Y., Hao, G., Zheng, J., & Tian, Y. (2016). CXCL5 is a potential diagnostic and prognostic marker for bladder cancer patients. *Tumor Biology*, *37*(4), 4569–4577. https://doi.org/10.1007/s13277-015-4275-4

## **Figure legends**

Figure 1: PRISMA flow diagram showing the process of selecting included studies.

Figure 2: Assessing the of bias using QUADAS-2 tools

 Table 1: Summarized the data extracted from the included studies.